December 12, 2012: by Bill Sardi
MicroRNA studies conducted at the National Institutes of Health reveal one particular brand of resveratrol-based pill, Longevinex®, exhibits a distinctive gene activity pattern apart from plain resveratrol. In particular, Longevinex strongly inhibits production of gene proteins produced when tissues are deprived of oxygen and subsequently develop new abnormal blood vessels in an attempt to deliver O2 to tissues.
In the study published in PLoS ONE, just two microRNA represented over 90% of Longevinex’ broad gene activity. (Micro RNA are small RNA molecules that regulate gene activity.)